Your browser doesn't support javascript.
loading
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
Mateo, Joaquin; de Bono, Johann S; Fizazi, Karim; Saad, Fred; Shore, Neal; Sandhu, Shahneen; Chi, Kim N; Agarwal, Neeraj; Olmos, David; Thiery-Vuillemin, Antoine; Özgüroglu, Mustafa; Mehra, Niven; Matsubara, Nobuaki; Young Joung, Jae; Padua, Charles; Korbenfeld, Ernesto; Kang, Jinyu; Marshall, Helen; Lai, Zhongwu; Barnicle, Alan; Poehlein, Christian; Lukashchuk, Natalia; Hussain, Maha.
Afiliación
  • Mateo J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain.
  • de Bono JS; The Institute of Cancer Research and Royal Marsden, London, United Kingdom.
  • Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
  • Saad F; Centre de recherche du Centre Hospitalier de l'Université de Montréal/CRCHUM, Université de Montréal, Montreal, QC, Canada.
  • Shore N; Carolina Urologic Research Center, Myrtle Beach, SC.
  • Sandhu S; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Chi KN; BC Cancer Agency, Vancouver, BC, Canada.
  • Agarwal N; Huntsman Cancer Institute (NCI-CCC), University of Utah, Salt Lake City, UT.
  • Olmos D; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Thiery-Vuillemin A; Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France.
  • Özgüroglu M; Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Mehra N; Radboud University Medical Center, Nijmegen, the Netherlands.
  • Matsubara N; National Cancer Center Hospital East, Chiba, Japan.
  • Young Joung J; Center for Prostate Cancer, National Cancer Center, Goyang, Republic of South Korea.
  • Padua C; Cetus Medicina Oncologia, Betim, Brazil.
  • Korbenfeld E; Hospital Británico de Buenos Aires, Buenos Aires, Argentina.
  • Kang J; Global Medicines Development, Oncology R&D, AstraZeneca, Gaithersburg, MD.
  • Marshall H; AstraZeneca contracted through PHASTAR, Cambridge, United Kingdom.
  • Lai Z; 9Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Barnicle A; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Poehlein C; Merck & Co, Inc, Rahway, NJ.
  • Lukashchuk N; Global Medicines Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Hussain M; 1Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
J Clin Oncol ; 42(5): 571-583, 2024 Feb 10.
Article en En | MEDLINE | ID: mdl-37963304
ABSTRACT
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Límite: Humans / Male Idioma: En Revista: J Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: España
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Resistentes a la Castración Límite: Humans / Male Idioma: En Revista: J Clin Oncol Año: 2024 Tipo del documento: Article País de afiliación: España